Mallik Greene, Timo Pew, A Burak Ozbay, Durado Brooks, Jerry L Lovelace
{"title":"Improving CRC screening in an underserved population: real-world adherence to mt-sDNA testing among the incarcerated in Nebraska, United States.","authors":"Mallik Greene, Timo Pew, A Burak Ozbay, Durado Brooks, Jerry L Lovelace","doi":"10.1080/03007995.2025.2517696","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study assessed adherence to colorectal cancer (CRC) screening with a multi-target stool DNA (mt-sDNA) test in a real-world, carceral setting.</p><p><strong>Methods: </strong>This was a retrospective observational study in a prison system using laboratory data from Exact Sciences Laboratories LLC. Individuals aged 45-85 years incarcerated by the Nebraska Department of Correctional Services (Nebraska, United States) covered under a single National Provider Identifier were included. Participants underwent CRC screening evaluation at the prison's medical center (June 1, 2023-April 1, 2024). Adherence and the time to test return (days) were evaluated overall and across patient characteristics.</p><p><strong>Results: </strong>A total of 189 patients were included (50-64 years: 78.3%; male: 94.7%). Overall adherence was 92.6%. Adherence was numerically higher in those aged 65-75 years and in participants from rural and small-town correctional facilities (95.2% each). Mean overall time to test return from shipment of mt-sDNA kit to receipt of a valid test was 21 days, with numerically shortest time to test return in participants aged 45-49 years (18.8 days), from small-town correctional facilities (19.2 days), and females (17.3 days). Overall mt-sDNA test positivity rate was 17.7%.</p><p><strong>Conclusion: </strong>High rates of adherence to the mt-sDNA test were observed in an underserved, incarcerated population, suggesting the potential of this screening approach in increasing rates of CRC screening and completion in this population. Future investigation into the possible individual-, provider-, and system-level benefits that may be obtained through broader adoption of the mt-sDNA screening test is warranted.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"809-816"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2517696","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: This study assessed adherence to colorectal cancer (CRC) screening with a multi-target stool DNA (mt-sDNA) test in a real-world, carceral setting.
Methods: This was a retrospective observational study in a prison system using laboratory data from Exact Sciences Laboratories LLC. Individuals aged 45-85 years incarcerated by the Nebraska Department of Correctional Services (Nebraska, United States) covered under a single National Provider Identifier were included. Participants underwent CRC screening evaluation at the prison's medical center (June 1, 2023-April 1, 2024). Adherence and the time to test return (days) were evaluated overall and across patient characteristics.
Results: A total of 189 patients were included (50-64 years: 78.3%; male: 94.7%). Overall adherence was 92.6%. Adherence was numerically higher in those aged 65-75 years and in participants from rural and small-town correctional facilities (95.2% each). Mean overall time to test return from shipment of mt-sDNA kit to receipt of a valid test was 21 days, with numerically shortest time to test return in participants aged 45-49 years (18.8 days), from small-town correctional facilities (19.2 days), and females (17.3 days). Overall mt-sDNA test positivity rate was 17.7%.
Conclusion: High rates of adherence to the mt-sDNA test were observed in an underserved, incarcerated population, suggesting the potential of this screening approach in increasing rates of CRC screening and completion in this population. Future investigation into the possible individual-, provider-, and system-level benefits that may be obtained through broader adoption of the mt-sDNA screening test is warranted.
目的:本研究评估了在真实世界的癌症环境中,使用多靶点粪便DNA (mt-sDNA)测试进行结直肠癌(CRC)筛查的依从性。方法:这是一项基于监狱系统的回顾性观察性研究,使用了来自Exact Sciences Laboratories LLC的实验室数据。被美国内布拉斯加州惩教服务部(Nebraska Department of Correctional Services)监禁的年龄在45-85岁的个体被纳入单一的国家提供者标识符。参与者在监狱医疗中心接受了CRC筛查评估(2023年6月1日- 2024年4月1日)。对依从性和测试返回时间(天)进行总体和跨患者特征的评估。结果:共纳入189例患者(50-64岁:78.3%;男:94.7%)。总体依从性为92.6%。在65-75岁的参与者(95.2%)和来自农村和小城镇惩教机构的参与者(95.2%)中,依从性在数字上最高。从运送mt-sDNA试剂盒到收到有效检测的平均总测试时间为21天,其中45-49岁(18.8天)、来自小镇惩教设施(19.2天)和女性(17.3天)的测试返回时间最短。总mt-sDNA检测阳性率为17.7%。结论:在服务不足的监禁人群中,观察到mt-sDNA检测的高依从率,表明这种筛查方法在提高该人群CRC筛查率和完成率方面具有潜力。通过更广泛地采用mt-sDNA筛选测试,对可能的个人、提供者和系统级别的益处进行进一步的调查是有必要的。
期刊介绍:
Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance